Peptides DB
Research-centric peptide and protocol reference hub
Study 84 of 88HGH (Somatropin) literatureJournal of pediatric endocrinology & metabolism : JPEM · ObservationalHigh-impact journal2026

Long-acting growth hormone therapy in Chinese children with idiopathic short stature: efficacy evaluation and influencing factors.

LAGH therapy shows statistically significant improvements in height and growth velocity in Chinese children with idiopathic short stature compared to short-acting growth hormone.

Read at Journal of pediatric endocrinology & metabolism : JPEMAdd to compare

Where it sits

this study against the rest of the hgh (somatropin) corpus
4
Preclinical
59
Observational · this one
1
Open-label
15
Randomised
9
Reviews

Summary and findings

This study evaluated the efficacy of long-acting growth hormone (LAGH) therapy in 180 Chinese children with idiopathic short stature (ISS) over 12 months. The LAGH group showed improved height standard deviation score (HtSDS) and growth velocity (GV) compared to a control group receiving short-acting growth hormone. No therapeutic claims are made.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
-1.47 ± 0.31 HtSDS vs -1.63 ± 0.48 in control, p<0.001 after 12 monthsn=1802026

Abstract

The authors’ words, as Journal of pediatric endocrinology & metabolism : JPEM supplied them

<h4>Objectives</h4>Exogenous growth hormone (GH) supplementation is the primary strategy for treating idiopathic short stature (ISS). Although long-acting growth hormone (LAGH) has attracted considerable interest due to its reduced injection frequency, data on its comparative efficacy and long-term safety in Chinese children with ISS remain limited. This study aims to assess LAGH's efficacy in this population and identify the factors influencing therapeutic outcomes.<h4>Methods</h4>This study was a single-center, retrospective cohort study. It included 180 ISS children who received LAGH treatment in our hospital from January 2019 to December 2024. Based on age, gender, and height standard deviation score (HtSDS), a 1:1 propensity score matching (PSM) was conducted to select concurrent ISS patients receiving short-acting growth hormone (daily rhGH) treatment. Treatment efficacy was evaluated according to the changes in HtSDS and growth velocity (GV) before and after treatment, and multivariate regression analysis was used to identify factors influencing clinical efficacy.<h4>Results</h4>The average age of children in the LAGH group was 8.37 ± 2.49 years. After treatment, the LAGH group showed significantly higher HtSDS (-1.47 ± 0.31 vs. -1.63 ± 0.48, p<0.001) and GV (10.06 ± 1.69 vs. 9.24 ± 1.34, p<0.001) compared to the control group for 12 months. Pearson correlation analysis revealed that IGF-1 most correlated with GV (r=0.58, p<0.001). Multivariate regression showed GH efficacy positively correlated with ΔIGF-1 (β=0.42, p<0.001) and IGFBP-3 (β=0.28, p=0.002), negatively with age (β=-0.35, p<0.001).<h4>Conclusions</h4>LAGH demonstrates favorable therapeutic effects in ISS, and it holds the potential to benefit a greater number of Chinese pediatric patients affected by this condition.

Background

This paper addresses the efficacy of long-acting growth hormone therapy in treating idiopathic short stature in children, a condition where children are significantly shorter than their peers without an identifiable cause. Previous studies have shown that growth hormone supplementation can improve height, but data on long-acting formulations in specific populations, such as Chinese children, are limited. Understanding the efficacy and factors influencing treatment outcomes is crucial for optimizing care in this demographic.

Methods

The study was a single-center, retrospective cohort analysis involving 180 children diagnosed with idiopathic short stature who received long-acting growth hormone treatment from January 2019 to December 2024. A 1:1 propensity score matching was conducted to compare these children with those receiving daily short-acting growth hormone treatment based on age, gender, and height standard deviation score. Primary outcomes included changes in height standard deviation score and growth velocity after 12 months of treatment.

Results

The primary endpoint showed that the LAGH group had a height standard deviation score of -1.47 ± 0.31 compared to -1.63 ± 0.48 in the control group, with a statistically significant p-value of <0.001. Additionally, growth velocity was significantly higher in the LAGH group at 10.06 ± 1.69 cm/year versus 9.24 ± 1.34 cm/year in the control group, also with p<0.001. Correlation analysis indicated that IGF-1 levels had a strong positive correlation with growth velocity (r=0.58, p<0.001).

Interpretation

The findings indicate that long-acting growth hormone therapy may provide significant improvements in height and growth velocity compared to short-acting formulations, aligning with previous literature on growth hormone efficacy. However, while the statistical significance is clear, the clinical significance of the changes in height standard deviation score may be modest. The study's retrospective design and single-center nature limit the ability to generalize these results widely, and potential confounding factors should be considered.

Key findings

  • -1.47 ± 0.31 HtSDS vs -1.63 ± 0.48 HtSDS, p<0.001 after 12 months.
  • 10.06 ± 1.69 cm/year GV vs 9.24 ± 1.34 cm/year GV, p<0.001 after 12 months.
  • r=0.58, p<0.001 for IGF-1 correlation with GV.
  • β=0.42, p<0.001 for ΔIGF-1 correlation with GH efficacy.
  • β=-0.35, p<0.001 for age correlation with GH efficacy.

Limitations

  • single-center study limits generalizability
  • retrospective cohort design may introduce bias
  • short follow-up duration of 12 months
  • propensity score matching may not fully account for confounding factors

Elsewhere in the HGH (Somatropin) corpus

BDose optimization and safety of long-acting pegylated growth hormone in pubertal idiopathic short stature: A retrospective real-world group study.Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2026 · n=118 · ΔHtSDS: 0.98 ± 0.45 vs. 0.62 ± 0.42, p < 0.001 for high-dose vs. low-dose groups.HumanAOnce-weekly somatrogon versus daily somatropin in pediatric growth hormone deficiency: A systematic review and meta-analysis.Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2026 · Not reported in abstract.reviewDAn assessment of the global usability of quality-of-life questionnaires in children receiving recombinant growth hormone therapy.Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2026 · 24 (65%) had a reported completion time less than 15 min.reviewCDeciphering the In Vivo Fate of PEGylated rhGH via a Molecular Ruler-Based MS Strategy.Analytical chemistry · plasma half-life t1/2 = 26.83 hAnimalDGH-IGF-1 axis and rhGH outcomes in children with GHD, ISS and SGA: a systematic review and meta-analysis.Journal of pediatric endocrinology & metabolism : JPEM · 2026 · Complete GHD showed greater first-year height velocity (HV) than ISS (MD +0.80 cm/year; 95% CI 0.52-1.08).reviewBInfluence of long-acting growth hormone analogs on other hypothalamic-pituitary axes: a real-world study.Journal of endocrinological investigation · 2026 · IGF-I SDS increased significantly in both groups (p<0.001).Human